Creo Medical Group plc provided revenue guidance for the year ending December 31, 2021. The group expects to report overall revenue for the year ended 31 December 2021, ahead of expectations, at just over £25 million, despite the well documented challenges related to COVID-19. Revenue from the company's core Creo product portfolio is growing and is in-line with management's cumulative revenue forecasts at the time of IPO in December 2016.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.25 GBX | -1.40% | +6.82% | -23.37% |
05-15 | Creo Medical on track to break even next year on strong 2023 results | AN |
05-15 | Creo Medical Group PLC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.37% | 159M | |
+75.35% | 12.54B | |
-23.21% | 7.71B | |
+7.39% | 6.72B | |
+13.59% | 5.38B | |
+34.82% | 4.89B | |
-15.69% | 4.71B | |
-25.08% | 3.75B | |
-26.74% | 2.77B | |
+51.57% | 2.55B |
- Stock Market
- Equities
- CREO Stock
- News Creo Medical Group PLC
- Creo Medical Group plc Provides Revenue Guidance for the Year Ending December 31, 2021